RADIOPHARMACEUTICALS AND DRUGS ELIGIBLE FOR CONTINUED SEPARATE MEDICARE PAYMENT ( 2 TO 3 Year Transitional Period )
|
|
- Cody Erick Tate
- 5 years ago
- Views:
Transcription
1 NUCLEAR MEDICINE APC TASK FORCE American College of Nuclear Physicians American Society of Nuclear Cardiology Council on Radionuclides and Radiopharmaceuticals, Inc. Academy of Molecular Imaging Society of Nuclear Medicine Society of Nuclear Medicine - Technologist Section Q3007 Payment Correction (SNM Chart) June 24, Samuel Morse Drive Reston, VA (703) Fax: (703) April 1, 2002 RADIOPHARMACEUTICALS AND DRUGS ELIGIBLE FOR CONTINUED SEPARATE MEDICARE ( 2 TO 3 Year Transitional Period ) We suggest that you monitor the SNM web page for updated information at Average Wholesale Price (AWP) updates may be made to the REDBOOK at any time. Medicare payment is currently based on 95% of AWP. Addendum B Calendar Year 2002 Hospital Outpatient Payment Rates, effective April 1, 2002: Technical Corrections to Calendar Year 2002 Hospital Outpatient Payment Rates: 2002 Update of the Hospital Outpatient Prospective Payment System (OPPS), CMS Memorandum A , March 28, 2002, effective April 1, Pro-rata in Drug and Device Pass-Through Payments: The final rule published in the Federal Register on March 1, 2002, announced a uniform reduction of 63.6% to be applied to each of the transitional pass-through payments for drugs and devices provided on or after April 1, The Federal Registers published on November 1, 2001, November 30, 2001 and March 1, 2002 provide a full discussion of these reductions. There are several different pro-rata reduction-based formulas dependent on the sole source, generic or multi-source, and/or other classification of the drug/device category. Example of a sole-source drug pass-through pro-rata reduction can be found at the end of the radiopharmaceutical chart. Note: CMS short description limited by field size, details of long description for each radiopharmaceutical:
2 A4641 N Diagnostic Imaging Agent A4642 Deleted Replaced by C $1, $1, Satumomab Pendetide not otherwise classified Supply of Satumomab Pendetide, Radiopharmaceutical Diagnostic Imaging Agent, per dose A9500 G 1600 $ $ Technetium Tc99m Sestimibi Technetium Tc99m Sestimibi, per dose ONCOSCINT CARDIOLITE A9502 G 0705 $ $93.00 Technetium Tc99m tetrofosmin, per dose Technetium Tc99m Tetrofosmin, per unit dose A9503 G 1601 $42.18 $32.00 Technetium Tc99m medronate, [per dose - up to 30 mci] Technetium Tc99m Medronate, per dose (up to 30 mci) A9504 G 1602 $ $ Technetium Tc99m apcitide, per vial A9505 G 1603 $78.16 $51.00 Multi-source drug Technetium Tc99m Apcitide, per vial Tl-201, per mci Thallous Chloride Tl201, per mci MYOVIEW MDP ACUTECT THALLIUM 201
3 A9507 G 1604 $2, $1, In-111 capromab pendetide, per dose Indium 111 Capromab Pendetide, per dose A9508 G 1045 $ $ Iobenguane Sulfate I-131, per 0.5 mci Iobenguane Sulfate I-131, per 0.5 mci A9510 G 1205 $79.17 $65.00 Technetium Tc-99m Disofenin, per vial Disofenin, per vial A9511 G 1095 $38.00 $31.00 Technetium Tc99m Depreotide, per mci Technetium Tc99m Depreotide, per mci A9600 G 0701 $ $ Strontium-89 chloride, per mci Strontium-89 Chloride, per mci A9605 G 0702 $1, $ Samarium Sm153 Lexidronamm, per 50 mci C1058 G 1058 $36.74 $30.00 Tc99m oxidronate, per vial Samarium Sm153 Lexidronamm, per 50 mci PROSTASCINT Replaces C1045 Replace C1205 NEOTEC NEW code April 1, 2002 METASTRON QUADRAMET C1064 G 1064 $5.86 $4.00 I-131 Cap, each add l. mci New Descriptor C1065 G 1065 $15.81 $12.00 I-131 Sol, each add mci New Descriptor
4 C1066 G 1066 $1, $1, IN-111 Sataumomab Pendetide NEW C1079 G 1079 $ $ Co 57/58, 0.5 uci Indium 111 satumomab pendetide, per vial Cyanocobalamin Co 57/58, per 0.5 uci ONCOSCINT Nycomed C1087 G 1087 $0.65 $0.42 I-123 (capsule), per 100 mci, dx use I-123 Diagnostic C1090 Deleted D In-111 chloride, per mci Indium 111 Chloride, per mci C1091 G 1091 $ $ In-111 Oxyquinoline, per 0.5 mci C1092 G 1092 $ $ In-111 pentetate per 0.5 mci Indium 111 Oxyquinoline, per 0.5 mci Indium 111 Pentetate, per 0.5 mci C1094 G 1094 $33.09 $25.00 Tc99m Albumin Aggregate, 1.0 mci C1095 Use A9511 D 1095 $38.00 $31.00 Tc99m Depreotide, per vial Technetium Tc99m Albumin Aggregated, per 1.0 mci Technetium Tc99m Depreotide, per vial INDICLOR Used with WBC labeling Note Change in Description Indium DTPA MAA Note Change in Description Use A9511
5 C1096 G 1096 $ $ Tc99m Exametazime, per dose C1097 G 1097 $51.44 $42.00 Tc99m Mebrofenin, per vial C1098 G 1098 $22.43 $17.00 Tc99m Pentetate, per vial Technetium Tc99m Exametazime, per dose Technetium Tc99m Mebrofenin, per vial Technetium Tc99m Pentetate, per vial C1099 G 1099 $39.11 $32.00 Tc99m Pyrophosphate, per vial Technetium Tc99m Pyrophosphate, per vial C1122 G 1122 $1, $1,012 Tc99m Arcitumomab, per vial C1188 G 1188 $ $90.00 I-131 Cap, per 1-5 mci Technetium Tc99m Arcitumomab, per vial Sodium Iodide I-131, Capsule, per initial 1-5 mci C1200 G 1200 $22.61 $19.00 Tc99m Sodium Glucoheptonate C1201 G 1201 $ $ Tc99m Succimer, per vial Technetium Tc99m Sodium Glucoheptonate, per vial Technetium Tc99m Succimer, per vial CERETEC CHOLETEC Tc-99m DTPA PYROLITE CEA-SCAN Note Change in Description GLUCOSCAN DMSA
6 C1202 G 1202 $76.00 $59.00 Tc99m Sulfur Colloid, per dose Technetium Tc99m C1207 G 1207 $ $ Octreotide Acetate Depot 1 mg C1348 G 1348 $ C1775 NEW Multi-source drug Octreotide Acetate 1 mg I 131 Sol, per 1-6 mci G 1775 $ $ FDG, per dose (4-40 mci) Sodium Iodide I-131, Solution, per initial 1-6 mci Supply of radiopharmaceutical diagnostic imaging agent, fluorodeoxyglucose F18 (2-deoxy-2-[18F]fluoro-D-glucose), per dose (4-40 mci/ml) C9000 G 9000 $0.52 $0.42 Na Chromate Cr51, per 0.25 mci Injection, Sodium Chromate Cr51, per 0.25 mci C9013 G 9013 $81.10 $63.00 Co57 Cobaltous Chloride, per 10 uci Supply of Co57 Cobaltous Chloride, Radiopharmaceutical Diagnostic Imaging Agent, per uci C9100 G 9100 $10.34 $8.00 Iodinated I-131 albumin, per mci C9102 G 9102 $64.84 $ Na Chromate, per 50 mci Iodinated I-131 Albumin, per mci 51 Sodium Chromate, per 50 mci SULFUR COLLOID (SC) Somastatin Note Change in Description
7 C9103 G 9103 $17.18 $14.00 Na Iothalamate I-125, 10 µci J0150 K 0917 $17.82 Injection adenosine 6 mg J1245 K 0917 $17.82 Dipyridamole injection Q3002 G 1619 $25.62 $17.00 Multi-source drug Sodium Iothalmate I-125 Injection, per 10 uci Injection Adenosine, 6 mg (not to be used to report any adenosine phosphate compounds, instead use A9270) Injection, Dipyridamole, per 10 mg Gallium Ga-67, per mci Gallium Ga 67, per mci Q3003 G 1620 $ $ Technetium Tc99m Bicisate, per dose Q3004 G 1621 $29.93 $19.00 Multi-source drug Technetium Tc99m Bicisate, per unit dose Xenon Xe 133, per 10 mci Xenon Xe 133, per 10 mci Q3005 G 1622 $ $ Technetium Tc99 mertiatide, per mci Technetium Tc99m Mertiatide, per mci Q3006 G 1623 $22.61 $18.00 Technetium Tc99m Glucepatate Technetium Tc99m Glucepatate, per 5 mci Gallium NEUROLITE Xenon TECHNESON MAG-3 GLUCOSCAN
8 Q3007 G 1624 $81.10 $66.00 Sodium phosphate P-32 Q3008 G 1625 $ $ Indium 111-in Pentetreotide Sodium Phosphate P32, per mci Indium 111-In Pentetreotide, per 3 mci Q3009 G 1626 $1.47 $1.20 Technetium Tc99m Oxidronate Technetium Tc99m Oxidronate, per mci Q3010 G 1627 $40.90 $33.00 Tc-99m Labeled Red Blood Cells Q3011 G 1628 $ $ Chromic Phosphate P32 Q3012 G 3012 $81.10 $66.00 Co57, 0.5 mci Technetium Tc99m Labeled Red Blood Cells, per mci Chromic Phosphate P32 Suspension, per mci Cyanocobalamin Cobalt Co57, per 0.5 mci OCTREOSCAN HDP ULTRATAG Replaces C1089 April 1, 2002 The common and brand names for the chemicals and compounds listed were researched and added for your convenience. If there is a radiopharmaceutical missing from the list please, check the web site. Additional Notes: CMS has stated that hospitals should use revenue code 636 when reporting radiopharmaceuticals or drugs eligible on the pass-through list. Other Revenue Codes: Diagnostic nuclear medicine imaging procedure revenue code 340 and PET imaging procedure revenue code 404.
9 Status Indicators Indicator Service Status D Deleted Codes Are Deleted Effective with the Beginning of the Calendar Year E Non-Covered Items and Services Not Paid Under Outpatient PPS. G Drug/Biological Pass-Through Additional Payment K Non Pass-Through Drug/Biological Paid Under Outpatient PPS N Incidental services, packaged into APC rate Packaged S Significant Procedure, Not Discounted When Multiple Paid Under Outpatient PPS T Significant Procedure, Multiple Procedure Applies Paid Under Outpatient PPS X Ancillary Service Paid Under Outpatient PPS
10 Pro Rata Estimation Sole Source Radiopharmaceutical with AWP of $100 (example) By statute, the total Medicare payment is 95% of AWP (95% of AWP = total Medicare Payment) = $95.00 a. Calculate Acquisition costs (base APC payment using the AWP) ($100 x 0.68) = $68.00 b. Determine Pass-through portion (Total Medicare payment [95% of AWP] minus acquisition cost ($ $68.00) = $27.00 c. Calculate the pro rata reduction by multiplying the pass-through portion by (0.636 x $27.00) = $17.17 d. Calculate the new 2002 pass-through payment by subtracting the calculated pro rata reduction amount from the pass-through ($ $17.17) = $ 9.83 e. Calculated Acquisition costs + calculated new 2002 pass-through payment ($ $9.83) = Total Medicare Payment = $77.83 In this example, the hospital payment is reduced $17.17, representing an 18% reduction. You may also use the following formula to estimate payment for sole - source radiopharmaceuticals: Medicare Payment Rate x = New 2002 Payment with reduction ($77.83) Or 82% of the Medicare Payment Rate = New 2002 Payment with reduction ($77.90) Multi-Source Products: Multi-source products and products with generic competitors, the pro rata reduction is calculated differently, e.g. determine the passthrough portion of the Medicare payment which is the difference between the acquisition costs (5 times co-pay) and 95% of AWP, and calculate reduction.
NUCLEAR MEDICINE APC TASK FORCE
NUCLEAR MEDICINE APC TASK FORCE American College of Nuclear Physicians American Society of Nuclear Cardiology Council on Radionuclides and Radiopharmaceuticals, Inc. Academy of Molecular Imaging Society
More informationOfficial Listing of Radioactive Materials Approved for the Four Groups of Diagnostic Uses as Defined in 15A NCAC
Division of Environmental Health Radiation Protection Section Radioactive Materials Branch PUBLICATION 97-01 Official Listing of Radioactive Materials Approved for the Four Groups of Diagnostic Uses as
More informationNot Paid under Outpatient PPS. Deleted Effective Beginning of Calendar Year Not Paid under Outpatient PPS
Indicator A B Service Services furnished to a hospital outpatient that are paid under a fee schedule or payment system other than OPPS Codes that are not recognized by OPPS when submitted on an Outpatient
More informationContrast Agents and Radiopharmaceuticals 2017
Contrast Agents and Radiopharmaceuticals 207 Covered: Code Code Description Allow with Code(s) Code Description Max Units A464 Radiopharmaceutical, diagnostic, not otherwise classified n/a Invoice Req'd
More informationDeleted Effective Beginning of Calendar Year Not Paid under Outpatient PPS Not Paid Under OPPS or any other Medicare payment system
FINAL 2010 Compared to FINAL 2011 Rates Medicare Hospital Outpatient Prospective Payment System HOPPS (APC) Nuclear Medicine Procedures, Radiopharmaceuticals, and Drugs CMS Website HOPPS CY2011 FINAL Rule
More informationNUCLEAR MEDICINE APC TASK FORCE
NUCLEAR MEDICINE APC TASK FORCE Academy of Molecular Imaging American College of Nuclear Physicians American College of Radiology American Society of Nuclear Cardiology Council on Radionuclides and Radiopharmaceuticals,
More informationPaid under OPPS; separate APC payment. Separate cost-based pass-through payment; not subject to copayment. Paid under OPPS; separate APC payment
WWW.SM.ORG FIAL 2011 Compared to PROPOSED 2012 Rates Medicare Hospital Outpatient Prospective Payment System HOPPS (APC) uclear Medicine Procedures, Radiopharmaceuticals, and Drugs CMS Website HOPPS CY2012
More informationUpdated version
Indicator A D E FIAL 2015 Compared to FIAL 2016 s Medicare Hospital Outpatient Prospective System HOPPS (APC) uclear Medicine Procedures, Radiopharmaceuticals, and Drugs CY15 HOPPS Final Rule CY16 HOPPS
More informationUpdated July 3, 2014
WWW.SMMI.ORG Indicator A E G K Q1 T X For which pricing information is not available (ew in CY ) Click here for Link to References: CMS Website HOPPS CY Proposed Rule (Fed. Reg. Version add B) Service
More informationNuclear Cardiology Reimbursement. Todd Lamb, BS, AS, CNMT Clinical Operations Mgr Regions Hospital St. Paul, MN
Nuclear Cardiology Reimbursement Todd Lamb, BS, AS, CNMT Clinical Operations Mgr Regions Hospital St. Paul, MN Slides are not to be reproduced without the permission of the author Slides are not to be
More informationUpdated January 6, 2015
WWW.SMMI.ORG Indicator A D E G K Q1 S T U X Items, Codes, and Services: FIAL Compared to FIAL 2015 s Medicare Hospital Outpatient Prospective System HOPPS (APC) uclear Medicine Procedures, Radiopharmaceuticals,
More informationClick here for Link to References: CMS Website HOPPS CY 2014 Final Rule (Fed. Reg. Version add B) Updated November 27, 2013
WWW.SMMI.ORG Indicator A E G K Q1 T X FIAL Compared to FIAL 2014 s Medicare Hospital Outpatient Prospective System HOPPS (APC) uclear Medicine Procedures, Radiopharmaceuticals, and Drugs Services furnished
More informationClick here for Link to References: CMS Website HOPPS CY 2018 Final Rule. CMS Website HOPPS CY2018 Final Rule Updated November 2017.
Final Compared to 3Q 2017 Rates Medicare Hospital Outpatient Prospective Payment System HOPPS () Nuclear Cardiology Procedures, Radiopharmaceuticals, and Drugs Click here for Link to References: CMS Website
More informationUpdated July 6, 2012 CMS ADDENDUM D1. Final OPPS Payment Status Indicators for CY Not paid under OPPS or any other Medicare Payment System.
WWW.SM.ORG Indicator A B D E G H K Q1 S T U X Services furnished to a hospital outpatient that are paid under a fee schedule or payment system other than OS Codes that are not recognized by OS when submitted
More informationSUGGESTED PRESCRIBED DOSAGE LIST
approved and issued by a noted Authorized User on your Materials License. CENTRAL NERVOUS SYSTEM Brain Metabolism Brain Perfusion Cisternography Ventricular Shunt 18 F-FDG 10-20 mci (370 740 MBq) 99m Tc
More informationWater Any Inulin IV Normal renal function Inulin IV Abnormal renal function Glucose IV Normal Carfentanil IV 17.
Table 1: Effective Dose Equivalent (HE) values for common procedures involving the use of radiopharmaceuticals. Listings (last column) are averaged over both sexes, and are computed for adult subjects.
More informationFDA-approved radiopharmaceuticals
FDA-approved radiopharmaceuticals Medication Management This is a current list of all FDA-approved radiopharmaceuticals. Nuclear medicine practitioners that receive radiopharmaceuticals that originate
More informationSteven G. Marsh MS, DABMP, Medical Health Physics RSO - Baystate Health Springfield, MA
Steven G. Marsh MS, DABMP, Medical Health Physics RSO - Baystate Health Springfield, MA Radioactive Materials License: NRC or Agreement State Broad Scope & Medical Component Limited License Regulations
More informationE LT O N A. M O S M A N OUTLINE
34 NUCLEAR MEDICINE E LT O N A. M O S M A N OUTLINE Principles of nuclear medicine, 388 Historical development, 389 Comparison with other modalities, 390 Physical principles of nuclear medicine, 392 Radiation
More informationComponents of Preparedness
Components of Preparedness Domain I: Radiation Physics & Detection 7% Domain II: Radiation Safety & Regulations 13% Domain III: Pharmaceutical & Radiopharmaceutical Agents 25% Domain IV: Instrument Operations
More informationRadiopharmaceutical Administration Radiation Dose Reporting. RARD Reporting White Paper
Radiopharmaceutical Administration Radiation Dose Reporting RARD Reporting White Paper A RARD report proposes a solution to connect the radiopharmaceutical management dominion with the image modalities
More informationRadTool Nuclear Medicine Flash Facts
RadTool Nuclear Medicine Flash Facts Bital Savir-Baruch Bruce J. Barron RadTool Nuclear Medicine Flash Facts Illustrations by Eric Jablonowski Bital Savir-Baruch Loyola University Medical Center Maywood
More informationProcedure Guidelines. Nuclear Medicine
Procedure Guidelines Nuclear Medicine Dutch Society of Nuclear Medicine Procedure Guidelines Nuclear Medicine Dutch Society of Nuclear Medicine Editor-in-chief: JP Esser I Diagnostic Methods II Radionuclide
More informationExcretion Factors: the percentage of administered radioactivity released to sewer for routinely used radiopharmaceuticals.
Institute of Ph ysics and Engineering in M edicine 1. Background ADVICE NOTICE: Excretion Factors: the percentage of administered radioactivity released to sewer for routinely used radiopharmaceuticals.
More informationRecent initiatives of the FANC. Michel Biernaux Health Protection Service Health and Environment Department
Recent initiatives of the FANC Michel Biernaux Michel.biernaux@fanc.fgov.be Health Protection Service Health and Environment Department Reminder objectives of the national survey : 1.Review the average
More informationCardiovascular nuclear imaging employs non-invasive techniques to assess alterations in coronary artery flow, and ventricular function.
National Imaging Associates, Inc. Clinical guidelines CARDIOVASCULAR NUCLEAR MEDICINE -MYOCARDIAL PERFUSION IMAGING -MUGA Original Date: October 2015 Page 1 of 9 FOR CMS (MEDICARE) MEMBERS ONLY CPT4 Codes:
More informationUpdated work programme of the European Pharmacopoeia
Pharmeuropa Useful information February 2017 1 Updated work programme of the European Pharmacopoeia (November 2016) The following items have been added to or deleted from the work programme during the
More information2017 St. Luke's-Roosevelt Nuclear Medicine Department Procedure Catalog. meds
2017 St. Luke's-Roosevelt Nuclear Medicine Department Procedure Catalog Procedure Name Patient Preparation Cardiac Studies Stress Myocardial Perfusion Study Gated pool study (MUGA) Myocardial Cell Damage
More informationHealth Concerns Related to Radiation Exposure. of the Female Nuclear Medicine Patient. Michael G. Stabin
Health Concerns Related to Radiation Exposure of the Female Nuclear Medicine Patient Michael G. Stabin Radiation Internal Dose Information Center Oak Ridge Institute for Science and Education P.O. Box
More informationAustin Radiological Association Nuclear Medicine Procedure WHITE BLOOD CELL MIGRATION STUDY (In-111-WBCs, Tc-99m-HMPAO-WBCs)
Austin Radiological Association Nuclear Medicine Procedure WHITE BLOOD CELL MIGRATION STUDY (In-111-WBCs, Tc-99m-HMPAO-WBCs) Overview Indications The White Blood Cell Migration Study demonstrates the distribution
More informationOTHER NON-CARDIAC USES OF Tc-99m CARDIAC AGENTS Tc-99m Sestamibi for parathyroid imaging, breast tumor imaging, and imaging of other malignant tumors.
DEFINITION OF CARDIAC RADIOPHARMACEUTICAL: A radioactive drug which, when administered for purpose of diagnosis of heart disease, typically elicits no physiological response from the patient. Even though
More informationApligraf A Reimbursement Case Study Antonio S. Montecalvo, CPA Director of Customer Support Services ISCT San Diego - May 5th, 2009
Apligraf A Reimbursement Case Study Antonio S. Montecalvo, CPA Director of Customer Support Services ISCT San Diego - May 5th, 2009 Key Points Current Business Reimbursement Landscape FDA Approval Hospital
More informationRelease of Patients or Human Research Subjects Administered Radioactive Materials
Release of Patients or Human Research Subjects Administered Radioactive Materials Section (41) (a), "Release of Individuals Containing Radioactive Drugs or Implants," of Chapter 420-3-26 of the Rules published
More informationPrior Authorization for Non-emergency Cardiac Imaging Procedures
Attention: All Providers Prior Authorization for Non-emergency Cardiac Imaging Procedures The N.C. Medicaid Program is considering implementation of a prior authorization (PA) program for non-emergency
More informationCardiovascular nuclear imaging employs non-invasive techniques to assess alterations in coronary artery flow, and ventricular function.
National Imaging Associates, Inc. Clinical guidelines CARDIOVASCULAR NUCLEAR MEDICINE -MYOCARDIAL PERFUSION IMAGING -MUGA CPT4 Codes: Refer to pages 6-9 LCD ID Number: L33960 J 15 = KY, OH Responsible
More informationDose Estimates for Nuclear Medicine Procedures: What are they? Where do they come from?
Dose Estimates for Nuclear Medicine Procedures: What are they? Where do they come from? SNM Continuing Education Lecture Salt Lake City, UT -- June 6, 2010 Darrell R. Fisher Pacific Northwest National
More information2018 Medicare Nuclear Medicine Reimbursement Information
2018 Medicare Nuclear Medicine Reimbursement Information If you have questions regarding reimbursement for Lantheus Medical Imaging products, call Randy VanCoughnett at 978-436-7995 or email randy.vancoughnett@lantheus.com.
More informationAnthem Blue Cross and Blue Shield Virginia Advanced Imaging Procedures Requiring Precertification Revised 02/13/2013
Anthem Blue Cross and Blue Shield Virginia Advanced Imaging Procedures Requiring Precertification Revised 02/13/2013 Modality and CT Head CTA Head: Cerebrovascular MRI Head MRA Head: Cerebrovascular Functional
More informationRADIOTRACERS FOR MYOCARDIAL PERFUSION IMAGING
RADIOTRACERS FOR MYOCARDIAL PERFUSION IMAGING RAYMOND TAILLEFER, M.D. FRCP(c), ABNM DIRECTOR, DEPARTMENT OF NUCLEAR MEDICINE HOPITAL ST-JEAN-SUR-RICHELIEU Disclosures to Report: Grant Research Support:
More informationITEM WRITERS' GUIDELINES. for the PET SPECIALTY EXAM. offered by the NUCLEAR MEDICINE TECHNOLOGY CERTIFICATION BOARD
ITEM WRITERS' GUIDELINES for the PET SPECIALTY EXAM offered by the NUCLEAR MEDICINE TECHNOLOGY CERTIFICATION BOARD The purpose of this guide is to assist item writers in developing test questions (items)
More informationPRODUCT CATALOGUE. A complete palette in Nuclear Medicine. Oncology. Cardiology. Neurology
PRODUCT CATALOGUE A complete palette in Nuclear Medicine Oncology Cardiology Neurology INTERNATIONAL CATALOGUEALOGUE This is a comprehensive list of all products. Some products may not be available in
More informationRadiopharmaceutical Activities Administered for Diagnostic and Therapeutic Procedures in Nuclear Medicine in Argentine: Results of a National Survey
Radiopharmaceutical Activities Administered for Diagnostic and Therapeutic Procedures in Nuclear Medicine in Argentine: Results of a National Survey A. M. Bomben, C. A. Chiliutti Autoridad Regulatoria
More informationAvailability and Use of Medical Isotopes in Canada Performed as part of a Radiological Terrorism Risk Assessment
Availability and Use of Medical Isotopes in Canada Performed as part of a Radiological Terrorism Risk Assessment Carey L. Larsson Defence R&D Canada Ottawa TECHNICAL MEMORANDUM DRDC Ottawa TM 2004-218
More informationGastrointestinal tract
Gastrointestinal tract Colloidal liver-spleen imaging Presented by: Jehad Felemban Introduction: To obtain better anatomic display of liver and spleen architecture, we use (CT Ultrasound). (Radionuclide
More informationPATIENT DOSES DUE TO DIAGNOSTIC NUCLEAR MEDICINE EXAMINATIONS IN LITHUANIA
PATIENT DOSES DUE TO DIAGNOSTIC NUCLEAR MEDICINE EXAMINATIONS IN LITHUANIA Vaida Grigonienė, A. Čepulienė, F. Sakalauskas, J. Marcinkevičius, J. Žiliukas Kaunas, 2012 1 Radiation protection Efficient radiation
More informationContributions of Nuclear Isotopes in Medicine, a Perspective
Contributions of Nuclear Isotopes in Medicine, a Perspective February 21, 2012 at American Nuclear Society, CT Section David W. Cheng, MD, PhD Associate Professor of Diagnostic Radiology Chief of Nuclear
More informationAustin Radiological Association Nuclear Medicine Procedure PROSTATE CANCER STUDY (In-111-Capromab Pendetide [ProstaScint ])
Austin Radiological Association Nuclear Medicine Procedure PROSTATE CANCER STUDY (In-111-Capromab Pendetide [ProstaScint ]) Overview Indications The Prostate Cancer Study with an indium-111 labeled murine
More informationSummary of the Final 2013 Policy, Payment Changes For Hospital Outpatient Departments
Summary of the Final 2013 Policy, Payment Changes For Hospital Outpatient Departments A. Introduction On November 1, 2012, the Centers for Medicare & Medicaid Services (CMS) issued a final rule that will
More informationTHE PARATHYROID GLAND THEORY AND NUCLEAR MEDICINE PRACTICE
THE PARATHYROID GLAND THEORY AND NUCLEAR MEDICINE PRACTICE George N. Sfakianakis MD Professor of Radiology and Pediatrics Director, Division of Nuclear Medicine UM/JMMC Miami FL October 2009 ENDONCRINE
More informationITAP MANAGED CARE WORKING GROUP. TASK TEAM 1: CHRONIC DISEASE CONDITIONS (CDL s) GLAUCOMA
ITAP TT1 MC - Glaucoma Sept 17 ITAP MANAGED CARE WORKING GROUP TASK TEAM 1: CHRONIC DISEASE CONDITIONS (CDL s) GLAUCOMA Explanatory note to the Managed Care minimum reporting data specification (excel
More informationAdverse Reactions to Radiopharmaceuticals
FABAD J. Pharm. Sci., 37, 43-59, 2012 RESEARCH ARTICLE Adverse Reactions to Radiopharmaceuticals Gürhan ABUHANOĞLU*, A. Yekta ÖZER* Adverse Reactions to Radiopharmaceuticals Summary As the widespread use
More informationNUCLEAR CARDIOLOGY UPDATE
Nuclear Cardiology David K. Shelton, Jr., MD NUCLEAR CARDIOLOGY UPDATE No Conflicts. No Disclosures. No Smoking. David K. Shelton UCDMC Nuclear Cardiology Nuclear Cardiology Radionuclide Ventriculography
More informationSacred Heart Hospital on the Emerald Coast
- Nuclear Medicine - Regular Hours: 7:30 am 4:30 pm Monday Friday See *1 Scheduling/Orders: Ph. (850) 278-3800 Fax (850) 278-3787 Results: Health Information Mgmt (Med Records) Ph. (850) 278-3020 Contact
More informationNEUROLITE Technetium Tc-99m Bicisate dihydrochloride
NEUROLITE Technetium Tc-99m Bicisate dihydrochloride Consumer Medicine Information What is in this leaflet This leaflet answers some of the common questions about Neurolite. It does not contain all of
More informationDepartment of Nuclear Medicine with Positron Emission Tomography
(PET) Unit [1] Contact information: Registration: +48 41 367 4850 Main office: +48 41 367 4860 Fax: +48 41 367 4887 e-mail: zmnsco@onkol.kielce.pl [2] Head of the Department: Professor Janusz Braziewicz
More informationRadiopharmacy. Prof. Dr. Çetin ÖNSEL. CTF Nükleer Tıp Anabilim Dalı
Prof. Dr. Çetin ÖNSEL CTF Nükleer Tıp Anabilim Dalı What is Nuclear Medicine? Nuclear Medicine is the branch of medicine concerned with the use of radionuclides in the study and the diagnosis of diseases.
More informationUsing the evaluation point scale on the attached form, members may submit an application for Fellow Status. SNMMI-TS APPLICATION FOR FELLOW STATUS 1
In order to recognize members of the Technologist Section who have demonstrated leadership and have made a significant contribution to the profession of Nuclear Medicine Technology at the national level,
More informationINTERNAL DOSIMETRY IN NUCLEAR MEDICINE
BJRS BRAZILIAN JOURNAL OF RADIATION SCIENCES 01 (2013) 1-15 INTERNAL DOSIMETRY IN NUCLEAR MEDICINE Michael G. Stabin a a Vanderbilt University, Nashville, TN USA ABSTRACT This article reviews the current
More informationNuclear Medicine in Australia. Shaun Jenkinson
Nuclear Medicine in Australia Shaun Jenkinson Landmark Infrastructure for Australian Science OPAL Research Reactor Australian Synchrotron Camperdown Cyclotron Bragg Institute Centre for Accelerator Science
More informationRadioisotopes in Nuclear Medicine
Radioisotopes in Nuclear Medicine Anthony J. McGoron Florida International University Biomedical Engineering Institute 10555 West Flagler Street Miami, FL, 33199, USA 305-348-1352 Anthony.mcgoron@fiu.edu
More informationThe International Pharmacopoeia - Overview
The International Pharmacopoeia - Overview Caroline Mendy - Technical Officer Quality Assurance and Safety: Medicines World Health Organization 1 The International Pharmacopoeia Ph. Int. Scope WHO Consultative
More informationTumor Imaging in Nuclear Medicine: Current Status and
Tumor Imaging in Nuclear Medicine: Current Status and Future Prospects Bennett S. Greenspan, MD SNM MWM Albuquerque, NM January 30, 2010 Tumor Imaging Part I Current Status Current status agents that are
More informationBrain Perfusion SPECT
APPROVED BY: Director of Radiology Page 1 of 5 Brain Perfusion SPECT Primary Indications: Brain perfusion SPECT is most commonly performed (1) to aid in identification of the epileptogenic focus in patients
More informationWELCOME. To learn more or place an order, please call
PRODUCT CATALOG WELCOME OUR VALUES American Regent is committed to providing you with a growing and diversified portfolio of specialty injectable products to help meet the needs of today s ever-changing
More informationSCINTIGRAPHY OF THE CENTRAL NERVOUS SYSTEM Part 1: Introduction and BBB studies
SCINTIGRAPHY OF THE CENTRAL NERVOUS SYSTEM Part 1: Introduction and BBB studies George N. Sfakianakis MD Professor of Radiology and Pediatrics Director, Division of Nuclear Medicine October 2009 FIRST
More informationBasics of nuclear medicine
Basics of nuclear medicine Prof. dr. Davor Eterović Prof. dr. Vinko Marković Radioisotopes are used both in diagnostics and in therapy Diagnostics gamma emitters are used since gamma rays can penetrate
More informationNevro Reimbursement Support
HF10 therapy, delivered by the Nevro Senza System, is the high-frequency spinal cord stimulation technology operated at 10,000 Hz designed to aid in the management of chronic intractable pain of the trunk
More informationRadio-isotopes in Clinical Medicine
Radio-isotopes in Clinical Medicine Radiactive isotopes, whether naturally occurring or artificially produced, have a number of different uses in clinical medicine. These include: (1) Diagnostic and research
More informationCEREBRAL BLOOD FLOW AND METABOLISM
Supported by: HURO/0901/069/2.3.1 HU-RO-DOCS CEREBRAL BLOOD FLOW AND METABOLISM Part 3 Modern imaging methods SPECT, PET, nmri History of Nuclear Medicine Starts with the invention of the X-ray 1946: radioactive
More informationDose reduction has been a work in progress in pediatric
Pediatric Radiopharmaceutical Administered Doses: 2010 North American Consensus Guidelines Michael J. Gelfand 1, Marguerite T. Parisi 2, and S. Ted Treves 3 1 Section of Nuclear Medicine, Department of
More informationOverview Therapeutic Radiopharmaceuticals in Nuclear Medicine Definition: Characteristics of the Ideal Therapeutic Radiopharmaceutical
Overview After reviewing this tutorial, the users should be able to list the most important characteristics of the ideal therapeutic radiopharmaceutical and briefly discuss each of these as it relates
More informationJanuary Coding Guide. Pre-Treatment Mapping and Microspheres Administration. Hospital Outpatient, ASC and Physician Services
January 2018 Coding Guide Pre-Treatment Mapping and Microspheres Administration Hospital Outpatient, ASC and Services What are SIR-Spheres Y-90 resin microspheres? SIR-Spheres Y-90 resin microspheres are
More informationIsotopes in Functional Cancer Imaging
Seeing and Believing: i Medical Isotopes in Functional Cancer Imaging François Bénard, MD, FRCPC BCCancer Cancer Agency and University of British Columbia Nuclear Medicine 101 A radioactive atom is produced
More informationReferral Criteria for Nuclear Medicine Procedures
Introduction Referral Criteria for Nuclear Medicine Procedures This document provides advice for referrers to the at Hull & East Yorkshire Hospitals. Valid clinical indications are listed for routine diagnostic
More information2018 Cerebrovascular Reimbursement Coding Fact Sheet
The information contained in this document is provided for informational purposes only and represents no statement, promise, or guarantee by Cordis Corporation concerning levels of reimbursement, payment,
More informationOperational Issues Associated with the Medical Use of Radiopharmaceuticals and Brachytherapy
Chapter 9 Operational Issues Associated with the Medical Use of Radiopharmaceuticals and Brachytherapy Victoria Morris 9.1 INTRODUCTION This chapter first provides a brief background on the medical use
More informationDivision of Nuclear Medicine Procedure / Protocol
Division of Nuclear Medicine Procedure / Protocol MYOCARDIAL PLANAR STRESS &/OR REST CPT CODE: 78460-61, 78464-65, 78478, 78480 FOR USE WITH THALLIUM 201 AGENTS ONLY UPDATED: MARCH 2012 Indications: Diagnosis
More informationPart 7: Regulatory Issues and Quality Control. Part 1: Current NRC Regulations Related to Radiation Safety
Part 7: Regulatory Issues and Quality Control Part 1: Current NRC Regulations Related to Radiation Safety 1. Secretarial space, hallways, and certain other areas of a department must qualify as an UNRESTRICTED
More informationDual-Tracer Gated Myocardial Scintigraphy
APPROVED BY: Director of Radiology Page 1 of 7 Dual-Tracer Gated Myocardial Scintigraphy Primary Indications: Evaluation of myocardial perfusion and viability in patients with known or suspected coronary
More informationCoronary intravascular ultrasound (IVUS)
2017 Coding and Medicare payment guide Coronary intravascular ultrasound (IVUS) All coding, coverage, billing and payment information provided herein by Philips Volcano is gathered from third-party sources
More informationINFECTION CONTROL. In order to prevent contamination with blood products, the following protocol is to be observed:
Nuclear Medicine Protocols Contents 1. General: pgs 2-14 2. Skeletal: 15-20 3. Brain: 21-35 4. Renal: 36-58 5. Thyroid: 59-86 6. Respiratory: 87-99 7. Hepatobiliary: 100-109 8. Gatrointestinal: 110-117
More informationLumify. Lumify reimbursement guide {D DOCX / 1
Lumify Lumify reimbursement guide {D0672917.DOCX / 1 {D0672917.DOCX / 1 } Contents Overview 4 How claims are paid 4 Documentation requirements 5 Billing codes for ultrasound: Non-hospital setting 6 Billing
More informationDivision of Nuclear Medicine Procedure / Protocol
Division of Nuclear Medicine Procedure / Protocol MYOCARDIAL SPECT PERFUSION REST and REDISTRIBUTION CPT CODE: 78460, 78464 FOR USE WITH THALLIUM 201 ONLY UPDATED: MARCH 2012 Indications: Patient Prep:
More informationUpdate in Nuclear Cardiology: Patient-Centered Imaging Radiation Dose Reduction
Update in Nuclear Cardiology: Patient-Centered Imaging Radiation Dose Reduction E. Gordon DePuey, M.D. Icahn School of Medicine ant Mt. Sinai New York, NY Disclosures: Grant Support: Michael J. Fox Foundation
More informationRADIATION THERAPY SERVICES CSHCN SERVICES PROGRAM PROVIDER MANUAL
RADIATION THERAPY SERVICES CSHCN SERVICES PROGRAM PROVIDER MANUAL APRIL 2018 CSHCN PROVIDER PROCEDURES MANUAL APRIL 2018 RADIATION THERAPY SERVICES Table of Contents 34.1 Enrollment......................................................................
More informationPART I. RADIONUCLIDE THERAPY WITH I-131 SODIUM IODIDE: PATIENT & DOSE ADMINISTRATOR PRECAUTIONS; ADMINISTRATION METHODS
OVERVIEW AND TOPICS Patient and dose administrator precautions and dose administration methods of therapeutic procedures Administration methods for performing therapy with I-131 sodium iodide in either
More informationRadiation Therapy Services
Radiation Therapy Services Chapter.1 Enrollment..................................................................... -2.2 Benefits, Limitations, and Authorization Requirements...........................
More informationCODING SHEETS CHRONIC INTRACTABLE PAIN MANAGEMENT. Effective January 1, 2009 CODMAN 3000 NEUROMODULATION AND ONCOLOGY REIMBURSEMENT HOTLINE
CODING SHEETS CHRONIC INTRACTABLE PAIN MANAGEMENT Effective January 1, 2009 CODMAN 3000 NEUROMODULATION AND ONCOLOGY REIMBURSEMENT HOTLINE Phone: 800-609-1108 Email: codmanpump@aol.com Fax: 303-703-1572
More informationRADIONUCLIDE THERAPY FOR PALLIATION OF PAIN FROM BONY METASTASES
RADIONUCLIDE THERAPY FOR PALLIATION OF PAIN FROM BONY METASTASES Overview and Topics to Be Covered Reviews the use of radionuclide therapy in nuclear medicine for palliation of pain due to bony metastases.
More informationDiagnostic and interventional venous procedures (lower extremity)
2017 Coding and Medicare payment guide Diagnostic and interventional venous procedures (lower extremity) All coding, coverage, billing and payment information provided herein by Philips Volcano is gathered
More informationHF10 THERAPY 2018 Ambulatory Surgery Center Reimbursement and Coding Reference Guide
HF10 therapy, delivered by the Nevro Senza System, is the high-frequency spinal cord stimulation technology operated at 10,000 Hz designed to aid in the management of chronic intractable pain of the trunk
More informationPolicy. Number: (Replaces CPBs 239, 309, 320) *Please see amendment for Pennsylvania Medicaid at the end
1 of 99 Number: 0168 (Replaces CPBs 239, 309, 320) Policy *Please see amendment for Pennsylvania Medicaid at the end of this CPB. ProstaScint Aetna considers ProstaScint scans medically necessary for either
More information2019 Medicare Physician Fee Schedule -Final Relative Value Units and Payment Rates for Nuclear Cardiology Procedures
Myocardial Perfusion Imaging 0482T Absolute quant. Myocardial blood flow, PET PE Malpractice Total Conversion Factors $35.9996 $36.0391 78451-G SPECT MPI, single 1.38 8.5 0.10 9.98 $359.28 1.38 8.29 0.10
More information2 016 HF10 THERAPY HOSPITAL OUTPATIENT DEPARTMENT AND AMBULATORY SURGERY CENTER REIMBURSEMENT REFERENCE GUIDE
HF10 therapy, delivered by the Nevro Senza System, is a new high-frequency spinal cord stimulation technology designed to aid in the management of chronic intractable pain of the trunk/limbs, including
More informationRadionuclide & Radiopharmaceuticals
Radionuclide & Radiopharmaceuticals 1. Generator & Reactors 2. Cyclotrons & PET tracer 3. Quality control 4. Renal 5. GIT 6. CNS & Psychiatrics 7. Tumor Diagnosis & Treatment 8. Bones & joints 9. Thyroid
More information15 Annex - Energy 81. RULEBOOK ON APPLICATION OF IONISING RADIATION SOURCES IN MEDICINE
15 Annex - Energy 81. RULEBOOK ON APPLICATION OF IONISING RADIATION SOURCES IN MEDICINE RULEBOOK ON APPLICATION OF IONISING RADIATION SOURCES IN MEDICINE (Official Gazette of the Federal Republic of Yugoslavia
More informationCARDIAC PET PERFUSION IMAGING with RUBIDIUM-82
CARDIAC PET PERFUSION IMAGING with RUBIDIUM-82 Pr Denis AGOSTINI Président du Groupe de Cardiologie Nucléaire et IRM CHU Caen Bordeaux 2006 Cardiac Perfusion-Metabolism Mismatch with PET Cumulative Survival
More information32 CFR (a)(4), (a)(6)(iii), and (a)(6)(iv)
CHAPTER 15 SECTION 1 ISSUE DATE: November 6, 2007 AUTHORITY: 32 CFR 199.14(a)(4), (a)(6)(iii), and (a)(6)(iv) I. APPLICABILITY This policy is mandatory for the reimbursement of services provided either
More informationItroduction to the Nuclear Medicine: biophysics and basic principles. Zámbó Katalin Department of Nuclear Medicine
Itroduction to the Nuclear Medicine: biophysics and basic principles Zámbó Katalin Department of Nuclear Medicine NUCLEAR MEDICINE Application of the radioactive isotopes in the diagnostics and in the
More information2016 Billing and Coding Reference. Stereotactic Treatment Delivery
2016 Billing and Coding Reference Stereotactic Treatment Delivery This CY 2016 billing and coding reference is intended to be a general resource for physicians and reimbursement professionals and is current
More information